| Issue | Title | |
| Vol 2017, No 3 (2017) | Allergan Partners with Assembly Bio to Gain Microbiome Gastrointestinal Development Programmes | Abstract pdf html |
| Natasha Piper | ||
| Vol 2014, No 12 (2014) | Allergan Rebuffs Valeant and Agrees to US$66 B Actavis Deal | Abstract |
| Heather Cartwright | ||
| Vol 2012, No 9 (2012) | Allergan Strengthens its Ophthalmology Pipeline with US$1.5 B Alliance with Molecular Partners | Abstract |
| Heather Cartwright | ||
| Vol 2003, No 36 (2003) | Allergen and Acadia Enter Third Drug Discovery Collaboration | Abstract pdf |
| Business Review Editor | ||
| Vol 2003, No 34 (2003) | Alliance Management: Improving the chances of successful collaboration | Abstract |
| Business Review Editor | ||
| Vol 2004, No 53 (2004) | Alliances are Forever? | Details html |
| Fintan Walton | ||
| Vol 2011, No 7 (2011) | Allozyne to Go Public via Reverse Merger with Poniard Pharmaceuticals | Abstract |
| Heather Cartwright | ||
| Vol 2018, No 8 (2018) | Almirall Expands Pipeline with Allergan’s US Dermatology Portfolio in US$650 M Deal | Abstract pdf html |
| Michelle Liu | ||
| Vol 2006, No 69 (2006) | Almirall Prodesfarma SA | Abstract |
| Business Review Editor | ||
| Vol 2006, No 71 (2006) | Almirall Signs Deal with Forest for COPD Therapy | Abstract pdf |
| Business Review Editor | ||
| Vol 2004, No 50 (2004) | Alnylam and Merck Sign Second RNAi Agreement in 10 Months | Abstract pdf |
| Business Review Editor | ||
| Vol 2008, No 96 (2008) | Alnylam and Takeda Form RNAi Partnership | Abstract pdf html |
| Helen Scrutton | ||
| Vol 2012, No 11 (2012) | Alnylam Partners with Sanofi’s Genzyme to Advance its ALN-TTR Programme in Asia-Pacific | Abstract |
| Heather Cartwright | ||
| Vol 2002, No 31 (2002) | AlphaRx to License Anticancer Toxin from Select Therapeutics | Abstract pdf |
| Business Review Editor | ||
| Vol 2005, No 59 (2005) | ALTANA Pharma AG | Abstract pdf |
| Business Review Editor | ||
| Vol 2008, No 98 (2008) | Altea and Hospira Form a Transdermal Patch Partnership | Abstract pdf html |
| Taskin Ahmed | ||
| Vol 2005, No 59 (2005) | Alvesco (ciclesonide) | Abstract pdf |
| Business Review Editor | ||
| Vol 2007, No 90 (2007) | Alzheimer's - A Great Deal Still to be Done | Abstract pdf |
| Business Review Editor | ||
| Vol 2006, No 68 (2006) | Amarin and Multicell Sign Exclusive Licence Agreement for MS Fatigue Treatment | Abstract pdf |
| Business Review Editor | ||
| Vol 2005, No 65 (2005) | Amgen and Memory Pharmaceuticals to Develop Neurological Drugs | Abstract pdf |
| Business Review Editor | ||
| Vol 2013, No 9 (2013) | Amgen and Onyx Finally Agree to US$10.4 B Takeover | Abstract |
| Heather Cartwright | ||
| Vol 2016, No 10 (2016) | Amgen Bolsters its CV Pipeline with Arrowhead’s RNA Interference Therapies | Abstract pdf html |
| Jasmine Kalsi | ||
| Vol 2012, No 2 (2012) | Amgen Boosts its Oncology Pipeline with US$1.16 B Acquisition of Micromet | Abstract |
| Heather Cartwright | ||
| Vol 2004, No 47 (2004) | Amgen Boosts Long-Term Pipeline with US$1.3 B Tularik Acquisition | Abstract pdf |
| Business Review Editor | ||
| Vol 2021, No 6 (2021) | Amgen Continues to Grow Monoclonal Antibody Arsenal with Kirin’s KHK4083 | Abstract pdf html |
| Debadrita Paul | ||
| Vol 2022, No 2 (2022) | Amgen Delves into Protein Degrader Therapies with Plexium Collaboration | Abstract pdf html |
| Sasha Yachu | ||
| Vol 2012, No 1 (2012) | Amgen Enters Biosimilars Market with Watson Pharmaceuticals Collaboration | Abstract |
| Heather Cartwright | ||
| Vol 2003, No 40 (2003) | Amgen Enters metabolic Disease Market with Biovitrum Deal | Abstract pdf |
| Business Review Editor | ||
| Vol 2017, No 10 (2017) | Amgen Follows BMS’s Lead With a US$1.5 B Collaboration With CytomX | Abstract pdf html |
| Natasha Piper | ||
| Vol 2012, No 5 (2012) | Amgen Forays into Turkish Generics Market with MN Pharmaceuticals Purchase | Abstract |
| Heather Cartwright | ||
| Vol 2008, No 93 (2008) | Amgen Forced to Surrender Japan | Abstract pdf |
| Business Review Editor | ||
| Vol 2013, No 1 (2013) | Amgen Invests in Nanomedicine with BIND Biosciences Collaboration | Abstract |
| Heather Cartwright | ||
| Vol 2008, No 94 (2008) | Amgen Licenses Monoclonal Antibody from Kyowa Kakko | Abstract pdf |
| Business Review Editor | ||
| Vol 2004, No 44 (2004) | Amgen Licenses Stem Cell Growth Factors to ViaCell | Abstract pdf |
| Business Review Editor | ||
| Vol 2012, No 12 (2012) | Amgen Makes Long-Term Investment in Targeted Therapies with deCODE Genetics Purchase | Abstract |
| Heather Cartwright | ||
| Vol 2010, No 1 (2010) | Amgen Pushes Forward in Diabetes with Array Deal | Abstract |
| Taskin Ahmed | ||
| Vol 2016, No 8 (2016) | Amgen Shows Confidence in Advaxis’ Platform with $540 M Deal | Abstract pdf html |
| Dan Roberts | ||
| Vol 2011, No 2 (2011) | Amgen Signs Billion-Dollar Deal to Acquire BioVex for its Oncolytic Vaccine | Abstract |
| Heather Cartwright | ||
| Vol 2023, No 2 (2023) | Amgen Signs US$2 B Licensing Agreement with Synaffix for Next-Generation ADCs | Abstract pdf html |
| Lalit Mishra & Lucy Haggerty | ||
| Vol 2021, No 3 (2021) | Amgen Spends US$1.9 B on Five Prime to Boost Cancer Pipeline | Abstract pdf html |
| Michelle Liu | ||
| Vol 2018, No 12 (2018) | Amgen Terminates Advaxis Immunotherapy Collaboration and Other Deal Terminations | Abstract pdf html |
| Michelle Liu | ||
| Vol 2006, No 68 (2006) | Amgen to Acquire Abgenix for US$2.2 B | Abstract pdf |
| Business Review Editor | ||
| Vol 2019, No 9 (2019) | Amgen to Acquire Celgene’s Otezla® for US$13.4 B | Abstract pdf html |
| Michelle Liu | ||
| Vol 2022, No 12 (2022) | Amgen to Acquire Horizon Therapeutics for US$28.3 B | Abstract pdf html |
| Lucy Haggerty | ||
| Vol 2012, No 4 (2012) | Amgen to Acquire KAI Pharmaceuticals and Gain a Potential Successor to Sensipar® | Abstract |
| Heather Cartwright | ||
| Vol 2013, No 6 (2013) | Amgen to Re-Enter Japanese Market with Astellas Pharma Partnership | Abstract |
| Heather Cartwright | ||
| Vol 2007, No 85 (2007) | Amgen's Reality Check | Abstract pdf |
| Business Review Editor | ||
| Vol 2007, No 87 (2007) | Amgen’s Chances of Recovering from its Woes | Abstract |
| Business Review Editor | ||
| Vol 2015, No 9 (2015) | Amicus Expands Rare Disease Pipeline with Scioderm Acquisition | Abstract html |
| Heather Cartwright & Hardik Mewada | ||
| Vol 2006, No 77 (2006) | Amnesia | Details jpg |
| Business Review Editor | ||
| Vol 2022, No 5 (2022) | Amphista Enters Protein Degradation Collaborations with Bristol-Myers Squibb and Merck | Abstract pdf html |
| Lucy Haggerty | ||
| Vol 2004, No 52 (2004) | Ampligen (polyI:polyC12U) | Abstract pdf |
| Business Review Editor | ||
| Vol 2003, No 38 (2003) | Amrad and Merck in Deal to Develop New Asthma Drugs | Abstract |
| Business Review Editor | ||
| Vol 2007, No 81 (2007) | Amsterdam Molecular Therapeutics (AMT B.V.) | Abstract |
| Business Review Editor | ||
| Vol 2002, No 28 (2002) | Amsterdam Molecular Therapeutics Licenses Rights to IL-10 | Abstract pdf |
| Business Review Editor | ||
| Vol 2009, No 9 (2009) | Amylin Heads to India for Diabetes Developments | Abstract |
| Taskin Ahmed | ||
| Vol 2011, No 2 (2011) | Anacor and Medicis in US$160 M Acne Research Pact | Abstract |
| Heather Cartwright | ||
| Vol 2005, No 61 (2005) | Anadys Lands Lucrative HCV Deal with Novartis | Abstract pdf |
| Business Review Editor | ||
| Vol 2005, No 58 (2005) | Andrx Exits the Branded Drugs Business | Abstract |
| Business Review Editor | ||
| Vol 2006, No 76 (2006) | Angel | Details jpg |
| Business Review Editor | ||
| Vol 2012, No 3 (2012) | Angiochem Validates its EPiC Technology via Rare Disease Deal with GSK | Abstract |
| Heather Cartwright | ||
| Vol 2024, No 7 (2024) | ANI Pharmaceuticals to Acquire Alimera Sciences for US$381 M | Abstract pdf html |
| Ayush Saxena | ||
| Vol 2011, No 2 (2011) | ANNUAL REVIEW: Deal Making in 2010 | Abstract |
| Heather Cartwright | ||
| Vol 2012, No 1 (2012) | ANNUAL REVIEW: Deal Making in 2011 | Abstract |
| Heather Cartwright | ||
| Vol 2009, No 11 (2009) | Another GSK and Nabi Deal Sends Positive Smoke Signals | Abstract |
| Taskin Ahmed | ||
| Vol 2009, No 9 (2009) | Another Japanese Co Gets a Foothold in US Market | Abstract |
| Taskin Ahmed | ||
| Vol 2009, No 6 (2009) | Another Oncology Deal for Sanofi | Abstract |
| Taskin Ahmed | ||
| Vol 2005, No 63 (2005) | Antipodean Innovation | Details html |
| Fintan Walton | ||
| Vol 2007, No 84 (2007) | Antiques | Details jpg |
| Business Review Editor | ||
| Vol 2005, No 57 (2005) | Antisoma Acquires Aptamera | Abstract pdf |
| Business Review Editor | ||
| Vol 2009, No 6 (2009) | Antisoma Sells Oral Fludarabine to Sanofi-aventis | Abstract |
| Taskin Ahmed | ||
| Vol 2008, No 96 (2008) | Antisoma's Shares Rise as Company Announces Acquisition of Xanthus | Abstract pdf html |
| The PharmaDeals Team | ||
| Vol 2006, No 76 (2006) | Apotex vs. Large Pharma: The Battle Continues | Abstract |
| Business Review Editor | ||
| Vol 2006, No 75 (2006) | Apotex’s Confidence Scares Large Pharma | Abstract |
| Business Review Editor | ||
| Vol 2004, No 53 (2004) | Aradigm’s Confidence Boosted by Novo Nordisk | Abstract |
| Business Review Editor | ||
| Vol 2002, No 26 (2002) | Arakis and GeneFormatics Collaborate on Performance Enhanced Medicines | Abstract pdf |
| Business Review Editor | ||
| Vol 2005, No 59 (2005) | Arakis and Vectura in COPD Alliance with Novartis | Abstract pdf |
| Business Review Editor | ||
| Vol 2005, No 60 (2005) | Arakis Ltd | Abstract pdf |
| Business Review Editor | ||
| Vol 2007, No 85 (2007) | Arbelic (telavancin) | Abstract pdf |
| Business Review Editor | ||
| Vol 2008, No 99 (2008) | Archemix in Yet Another Deal for its Aptamer Technology | Abstract pdf html |
| Sally Mardikian PhD | ||
| Vol 2002, No 27 (2002) | Ardana Acquires Europeptides | Abstract |
| Business Review Editor | ||
| Vol 2002, No 30 (2002) | Ardana Bioscence to Distribute Striant™ Testosterone Product in Europe | Abstract pdf |
| Business Review Editor | ||
| Vol 2012, No 11 (2012) | Ardelyx Licenses NHE3 Inhibitor Programme to AstraZeneca in its First Major Deal | Abstract |
| Heather Cartwright | ||
| Vol 2006, No 78 (2006) | Are Purely Platform Technology Biotech Companies Playing a Shrinking Market? | Abstract pdf |
| Business Review Editor | ||
| Vol 2002, No 30 (2002) | Arena and Merck Collaborate on GPCRs | Abstract pdf |
| Business Review Editor | ||
| Vol 2002, No 25 (2002) | Arena in research collaboration with Ferring | Abstract pdf |
| Business Review Editor | ||
| Vol 2010, No 7 (2010) | Arena’s Anti-Obesity Drug Gets Commercial Partner before Approval Decision | Abstract |
| Staff Editor, | ||
| Vol 2006, No 77 (2006) | Argenta Discovery Ltd. | Abstract |
| Business Review Editor | ||
| Vol 2007, No 86 (2007) | ARIAD and Merck & Co. Enter into Global Co-Development Deal | Abstract pdf |
| Business Review Editor | ||
| Vol 2021, No 8 (2021) | Aridis Pharmaceuticals Licenses AstraZeneca’s late-stage monoclonal antibody, survatoxumab | Abstract pdf html |
| Neha Madhwani | ||
| Vol 2007, No 84 (2007) | ArQule and Kyowa Hakko Kogya Sign Exclusive Licence Agreement for Cancer Drug in Asia | Abstract pdf |
| Business Review Editor | ||
| Vol 2011, No 8 (2011) | Array BioPharma and Genentech Form Another Cancer Collaboration | Abstract |
| Heather Cartwright | ||
| Vol 2005, No 62 (2005) | Arrow and Novartis Agree on RSV | Abstract pdf |
| Business Review Editor | ||
| Vol 2005, No 62 (2005) | Arrow Therapeutics Ltd. | Abstract pdf |
| Business Review Editor | ||
| Vol 2003, No 37 (2003) | Artus Partners with Abbott Laboratories to Market SARS Diagnostic Test | Abstract pdf |
| Business Review Editor | ||
| Vol 2012, No 5 (2012) | ASLAN Pharmaceuticals Gains Third Pipeline Drug via Licensing Deal with Almirall | Abstract |
| Heather Cartwright | ||
| Vol 2011, No 11 (2011) | Aslan Pharmaceuticals Licenses Regional Rights to BMS’ Early-Stage Cancer Drug | Abstract |
| Heather Cartwright | ||
| Vol 2010, No 7 (2010) | Aspen Pharmacare Bids for Sigma’s Pharmaceuticals Division | Abstract |
| Heather Cartwright | ||
| Vol 2013, No 7 (2013) | Aspen Pharmacare Continues Global Expansion with Deal to Acquire Merck & Co. API Business | Abstract |
| Heather Cartwright | ||
| Vol 2020, No 2 (2020) | Assertio Sells Nucynta® Franchise to Collegium for US$375 M | Abstract html pdf |
| Michelle Liu | ||
| 401 - 500 of 2581 Items | << < 1 2 3 4 5 6 7 8 9 10 > >> | |